Ergomed : The stock forcefully approaches new pivot levels
| Entry price | Target | Stop-loss | Potential |
|---|
|
GBX 1,500 |
GBX 2,000 |
GBX 1,200 |
+33.33% |
|---|
Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Ergomed plc. The stock's technical chart pattern suggests however that the level will be broken.
Summary● The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
● Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
● With an expected P/E ratio at 53.06 and 44.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● The company's enterprise value to sales, at 5.97 times its current sales, is high.
● The company is highly valued given the cash flows generated by its activity.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
ERGOMED 
